Search Results 1891-1900 of 19639 for hemoglobin

1. A Phase 2 Study of Anti-PD-L1 Antibody Atezolizumab in Alveolar Soft Part Sarcoma - Mayo Clinic

   Hemoglobin ≥ 8 g/dL. Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) (however, patients with known Gilbert disease who have serum ...

2. A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma - Mayo Clinic

   Hemoglobin (HgB) > 9 g/dL. Must not have required transfusion of red blood cells within 1 week of baseline Hgb assessment. Patient has the following blood ...

3. XmAb®20717 Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer - Mayo Clinic

   * Hemoglobin level ≤ 9.0 g/dL * Absolute neutrophil count ≤ 1.7 × 109 for subjects who will receive cabazitaxel; \< 1.0 × 109/L for all others * Aspartate ...

4. A Study to Evaluate GB002 in Adults with Pulmonary Arterial Hypertension (PAH) - Mayo Clinic

   Hemoglobin (Hgb) concentration < 8.5 g/dL at screening. Evidence of active human immunodeficiency virus (HIV), Hepatitis B or Hepatitis C, or tuberculosis ...

5. Publications - Abhinav Khanna, M.D. - Mayo Clinic

   Hemoglobin A1c improvements and better diabetes-specific quality of life among participants completing diabetes self-management programs: a nested cohort ...

6. Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma (HIMALAYA) - Mayo Clinic

   Hemoglobin ≥ g/dL;; Absolute neutrophil count ≥000/μL;; Platelet count ≥5000/μL;; Total bilirubin (TBL) ≤.0× upper limit of normal (ULN);; AST and ALT ...

7. Phase 2b Study of Investigational Products in Participants with Interstitial Lung Disease Secondary to Systemic Sclerosis - Mayo Clinic

   ... hemoglobin; Meeting drug stabilization requirements, as applicable: Background mycophenolate, methotrexate, or azathioprine (no more than 1 therapy) for ≥ 6 ...

8. Single-Ascending Dose Study of JK07 in Subjects With HFpEF - Mayo Clinic

   or >480 pg/mL (if in atrial fibrillation or atrial flutter). 6. Body mass index (BMI) ≥18 kg/m2 and ≤45 kg/m2 7. Screening hemoglobin ≥9.0 g/dL ...

9. Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer - Mayo Clinic

   Hemoglobin ≥ 9.0 g/dL. Note: Transfusions will be allowed to achieve this. Transfusions will be permitted provided the patient has not received more than 2 ...

10. Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib - Mayo Clinic

    Hemoglobin ≥ 8.0 g/dL;; Total bilirubin ≤ 1.5 x the upper limit of the normal range (ULN);; Aspartate aminotransferase (AST) ≤ 3 x ULN;; Alanine ...